Literature DB >> 16427399

Clinical evaluation of traumatic central cord syndrome: emphasis on clinical significance of prevertebral hyperintensity, cord compression, and intramedullary high-signal intensity on magnetic resonance imaging.

Joonsuk Song1, Junichi Mizuno, Tatsushi Inoue, Hiroshi Nakagawa.   

Abstract

BACKGROUND: We evaluated the prognostic and clinical value of radiological findings including prevertebral hyperintensity (HI), cord compression, intramedullary high-signal intensity (IMHSI) and instability in patients with traumatic central cord syndrome without evidence of fracture and dislocation.
METHODS: The radiological and clinical findings of 23 patients who had undergone surgery between 1996 and 2002 were reviewed retrospectively. All of the patients underwent dynamic motion study and magnetic resonance (MR) imaging after trauma. Neurologic status was evaluated with American Spinal Injury Association motor score pre- and postoperatively and compared with the radiological findings. Anterior decompression and fusion were performed in 12 patients with 1- or 2-level lesions, and posterior decompression was done for 11 cases of multilevel lesions.
RESULTS: Prevertebral HI was found in 17 patients. Among them, instability was revealed in 11 patients. There was significant correlation between prevertebral HI and instability (P = .014). Cord compression was found in varying degrees in all patients on MR imaging. Intramedullary high-signal intensity was found preoperatively in 19 (83%) of 23 patients, and it was revealed at the most compressed level of the spinal cord in all cases. The neurologic level was consistent with the level of instability (100%), IMHSI (95%), and cord compression (87%). Mean American Spinal Injury Association motor scores in patients with instability were lower than in those without instability (P < .05).
CONCLUSIONS: The presence of prevertebral HI, IMHSI, and cord compression influenced the neurologic status of the patients. The instability was significantly associated with poor prognosis for neurologic outcome. Prevertebral HI on T2 MR imaging may be a possible indicator of instability in patients with central cord syndrome after hyperextension injury.

Entities:  

Mesh:

Year:  2006        PMID: 16427399     DOI: 10.1016/j.surneu.2005.06.045

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  6 in total

1.  Traumatic central cord syndrome after blunt cervical trauma: a pediatric case report.

Authors:  Natalia Betances Ramírez; Rafael E Arias-Berríos; Carmen López-Acevedo; Edwardo Ramos
Journal:  Spinal Cord Ser Cases       Date:  2016-12-15

2.  Hyperextension injury of the cervical spine with central cord syndrome.

Authors:  Crispin Thompson; José Filipe Gonsalves; David Welsh
Journal:  Eur Spine J       Date:  2014-07-31       Impact factor: 3.134

3.  Diagnosis and management of traumatic cervical central spinal cord injury: A review.

Authors:  Nancy E Epstein; Renee Hollingsworth
Journal:  Surg Neurol Int       Date:  2015-05-07

4.  Risk Factors for Poor Prognosis of Spinal Cord Injury without Radiographic Abnormality Associated with Cervical Ossification of the Posterior Longitudinal Ligament.

Authors:  Bing Cao; Fengning Li; Yifan Tang; Lianshun Jia; Xiongsheng Chen
Journal:  Biomed Res Int       Date:  2022-02-17       Impact factor: 3.411

5.  Differences between spinal cord injury and cervical compressive myelopathy in intramedullary high-intensity lesions on T2-weighted magnetic resonance imaging: A retrospective study.

Authors:  Naosuke Kamei; Kazuyoshi Nakanishi; Toshio Nakamae; Takayuki Tamura; Yuji Tsuchikawa; Taiki Moisakos; Takahiro Harada; Toshiaki Maruyama; Nobuo Adachi
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

6.  The influence of timing of surgery in the outcome of spinal cord injury without radiographic abnormality (SCIWORA).

Authors:  Can Qi; Hehuan Xia; Dechao Miao; Xingui Wang; Zengyan Li
Journal:  J Orthop Surg Res       Date:  2020-06-16       Impact factor: 2.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.